OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Entry into a Material Definitive Agreement
ITEM1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On December19, 2016, Orexigen Therapeutics, Inc. (the Company)
entered into a First Supplemental Indenture with U.S. Bank
National Association, as trustee (the Trustee) and collateral
agent, and certain holders of the Companys 0% Convertible Senior
Secured Notes due 2020. to the Supplemental Indenture, the
Indenture dated March21, 2016 (the Indenture) was amended as
follows: (i)the limitations on the Companys ability to prepay,
redeem or otherwise satisfy any indebtedness were amended to
permit the Company to repurchase a specified amount of its 2.75%
Convertible Senior Notes due 2020 (the Note Repurchase); and
(ii)the required restricted cash balance amounts were reduced by
the amount the Company spends on the Note Repurchase. The Company
filed the Indenture as an exhibit to its Current Report on
Form8-K filed on December March15, 2016.
A copy of the Supplemental Indenture is filed as an exhibit to
this Current Report on Form8-K and incorporated by reference
herein.
ITEM9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
|
Exhibit Number |
ExhibitDescription |
|
| 4.1 |
Supplemental Indenture, dated December19, 2016, among Orexigen Therapeutics, Inc., U.S. Bank National Association, as trustee and collateral agent, and certain holders of 0% Convertible Senior Secured Notes due 2020 |
About OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX)
Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Recent Trading Information
OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) closed its last trading session up +0.10 at 1.85 with 298,757 shares trading hands.